Science & Technology
SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia
Department of Health and Human Services — National Institutes of Health
Opportunity #: 2R44HL145948-02
Award Ceiling
$2.1M
Award Floor
$2.1M
Close Date
Nov 30, 2025
Total Funding
$2.1M
Expected Awards
1
Posted Date
Jun 1, 2023
Cost Sharing Required
No
Grants.gov ID
sbir-2R44HL145948-02
Description
SBIR Phase Phase II award: "SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia" awarded to Haima Therapeutics LLC in Cleveland, Ohio. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $2,129,415. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, Women-owned businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.